Home LiteratureArticle Details
PMID: 24888894 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Early onset epileptic encephalopathy caused by de novo SCN8A mutations.

Epilepsia ·Vol. 55 ·No. 7 ·2014-07-00 ·Pages 994-1000

Ohba C, Kato M, Takahashi S, Lerman-Sagie T, Lev D, Terashima H, Kubota M, Kawawaki H, Matsufuji M, Kojima Y, Tateno A, Goldberg-Stern H, Straussberg R, Marom D, Leshinsky-Silver E, Nakashima M, Nishiyama K, Tsurusaki Y, Miyake N, Tanaka F, Matsumoto N, Saitsu H

Abstract

De novo SCN8A mutations have been reported in patients with epileptic encephalopathy. Herein we report seven patients with de novo heterozygous SCN8A mutations, which were found in our comprehensive genetic analysis (target capture or whole-exome sequencing) for early onset epileptic encephalopathies (EOEEs). A total of 163 patients with EOEEs without mutations in known genes, including 6 with malignant migrating partial seizures in infancy (MMPSI), and 60 with unclassified EOEEs, were analyzed by target capture (28 samples) or whole-exome sequencing (135 samples). We identified de novo SCN8A mutations in 7 patients: 6 of 60 unclassified EOEEs (10.0%), and one of 6 MMPSI cases (16.7%). The mutations were scattered through the entire gene: four mutations were located in linker regions, two in the fourth transmembrane segments, and one in the C-terminal domain. The type of the initial seizures was variable including generalized tonic-clonic, atypical absence, partial, apneic attack, febrile convulsion, and loss of tone and consciousness. Onset of seizures was during the neonatal period in two patients, and between 3 and 7 months of age in five patients. Brain magnetic resonance imaging (MRI) showed cerebellar and cerebral atrophy in one and six patients, respectively. All patients with SCN8A missense mutations showed initially uncontrollable seizures by any drugs, but eventually one was seizure-free and three were controlled at the last examination. All patients showed developmental delay or regression in infancy, resulting in severe intellectual disability. Our data reveal that SCN8A mutations can cause variable phenotypes, most of which can be diagnosed as unclassified EOEEs, and rarely as MMPSI. Together with previous reports, our study further indicates that genetic testing of SCN8A should be considered in children with unclassified severe epilepsy.

Keywords
De novo mutation Early onset epileptic encephalopathies SCN8A
MeSH Terms
Adolescent Child Child, Preschool Early Diagnosis Electroencephalography/methods Epilepsy/complications,diagnosis,genetics Female Humans Infant Intellectual Disability/diagnosis,etiology,genetics Male Mutation, Missense/genetics NAV1.6 Voltage-Gated Sodium Channel/genetics Phenotype Spasms, Infantile/complications,diagnosis,genetics
Chemicals
NAV1.6 Voltage-Gated Sodium Channel SCN8A protein, human
Authors & Affiliations
22 authors, click to expand affiliations / ORCID
Ohba Chihiro
Department of Human Genetics, Graduate School of Medicine, Yokohama City University, Yokohama, Japan; Department of Clinical Neurology and Stroke Medicine, Yokohama City University, Yokohama, Japan.
Kato Mitsuhiro
Takahashi Satoru
Lerman-Sagie Tally
Lev Dorit
Terashima Hiroshi
Kubota Masaya
Kawawaki Hisashi
Matsufuji Mayumi
Kojima Yasuko
Tateno Akihiko
Goldberg-Stern Hadassa
Straussberg Rachel
Marom Dafna
Leshinsky-Silver Esther
Nakashima Mitsuko
Nishiyama Kiyomi
Tsurusaki Yoshinori
Miyake Noriko
Tanaka Fumiaki
Matsumoto Naomichi
Saitsu Hirotomo
Article Info
Journal
Epilepsia
Abbr.
Epilepsia
ISSN
1528-1167
Published
2014-07-00
Epub
2014-00-02
Pages
994-1000
Language
English
Region
United States
NLM ID
2983306R
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com